Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Feb 19, 2026, 16:01Honoring Black Pioneers in Hematology During Black History Month – ASH
-
Feb 19, 2026, 15:16Irina Pahlevanyan: Global Leaders on Courage, Trust, and the True Purpose of Fundraising
-
Feb 19, 2026, 15:12Stéphanie Forté: Transition Readiness in Youth With Sickle Cell Disease
-
Feb 19, 2026, 15:08Tagreed Alkaltham: Strengthening Blood Inventory Governance Through RFID Technology
-
Feb 19, 2026, 14:59Başak Taburoğlu Yılmaz: Improving Diagnosis and Care for Women With Bleeding Disorders
-
Feb 19, 2026, 14:59Munira Borhany: Moving Beyond Stereotypes in the Diagnosis of Bleeding Disorders
-
Feb 19, 2026, 14:56Flora Peyvandi: Personalized VWF Dosing Revolutionizes Surgery in VWD
-
Feb 19, 2026, 14:54Michela Mazzon: The Molecular Trigger Behind the COVID19 Vaccines-Associated ITT
-
Feb 19, 2026, 14:42Luca Palombi: Real-Time Assessment of Venous Hemodynamics During Movement With DUS